stoxline Quote Chart Rank Option Currency Glossary
  
iTeos Therapeutics, Inc. (ITOS)
8.3  0.07 (0.85%)    12-11 16:00
Open: 8.24
High: 8.4
Volume: 406,721
  
Pre. Close: 8.23
Low: 8
Market Cap: 303(M)
Technical analysis
2024-12-11 4:44:09 PM
Short term     
Mid term     
Targets 6-month :  10.37 1-year :  11.34
Resists First :  8.88 Second :  9.71
Pivot price 8.27
Supports First :  7.53 Second :  6.27
MAs MA(5) :  8.25 MA(20) :  8.27
MA(100) :  11.93 MA(250) :  12.45
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  65.5 D(3) :  63.4
RSI RSI(14): 44.3
52-week High :  18.75 Low :  7.53
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ITOS ] has closed below upper band by 47.1%. Bollinger Bands are 77.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.41 - 8.45 8.45 - 8.48
Low: 7.9 - 7.94 7.94 - 7.99
Close: 8.23 - 8.3 8.3 - 8.36
Company Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Headline News

Thu, 05 Dec 2024
RA Capital Management L.P. Cuts Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat

Thu, 05 Dec 2024
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by Readystate Asset Management LP - MarketBeat

Tue, 26 Nov 2024
iTeos Therapeutics to Present at Evercore and Piper Sandler Healthcare Conferences - StockTitan

Tue, 26 Nov 2024
iTeos to Participate in Upcoming Investor Conferences - GlobeNewswire

Fri, 22 Nov 2024
BIOTECHNOLOGY VALUE FUND L P Increases Stake in ITeos Therapeuti - GuruFocus.com

Fri, 15 Nov 2024
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 37 (M)
Shares Float 24 (M)
Held by Insiders 0.7 (%)
Held by Institutions 103.9 (%)
Shares Short 2,210 (K)
Shares Short P.Month 3,820 (K)
Stock Financials
EPS -3.15
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 17.29
Profit Margin 0 %
Operating Margin -417.5 %
Return on Assets (ttm) -13.1 %
Return on Equity (ttm) -19.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.95
EBITDA (p.s.) -3.97
Qtrly Earnings Growth 0 %
Operating Cash Flow -117 (M)
Levered Free Cash Flow -91 (M)
Stock Valuations
PE Ratio -2.65
PEG Ratio 0
Price to Book value 0.48
Price to Sales 8.66
Price to Cash Flow -2.59
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android